NINLARO CAPSULE

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

IXAZOMIB (IXAZOMIB CITRATE)

Disponível em:

TAKEDA CANADA INC

Código ATC:

L01XG03

DCI (Denominação Comum Internacional):

IXAZOMIB

Dosagem:

3MG

Forma farmacêutica:

CAPSULE

Composição:

IXAZOMIB (IXAZOMIB CITRATE) 3MG

Via de administração:

ORAL

Unidades em pacote:

3

Tipo de prescrição:

Prescription

Área terapêutica:

ANTINEOPLASTIC AGENTS

Resumo do produto:

Active ingredient group (AIG) number: 0158410002; AHFS:

Status de autorização:

APPROVED

Data de autorização:

2016-08-04

Características técnicas

_NINLARO (as ixazomib citrate) capsules _
_Page 1 of 42_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
NINLARO
®
Ixazomib capsules
Capsules, 4 mg, 3 mg and 2.3 mg ixazomib (as ixazomib citrate), Oral
Antineoplastic Agent
Takeda Canada Inc.
22 Adelaide Street West, Suite 3800
Toronto Ontario M5H 4E3
Date of Initial Authorization:
Aug 3, 2016
Date of Revision:
Feb 02, 2024
Submission Control Number: 279731
NINLARO® and the NINLARO Logo® are registered trademarks of
Millennium Pharmaceuticals,
Inc.
TAKEDA™ and the TAKEDA Logo® are registered trademarks of Takeda
Pharmaceutical Company
Limited, used under license.
_NINLARO (as ixazomib citrate) capsules _
_Page 2 of 42_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Skin
02/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
.................................................................................................................
4
2.
CONTRAINDICATIONS
...................................................................................................
4
3.
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................................. 4
4
DOSAGE AND ADMINISTRATION
..................................................................................
5
4.1
Dosing Considerations
...........................................